Frankfurt - Delayed Quote • EUR NanoString Technologies, Inc. (0F1.F) Follow 0.1320 0.0000 (0.00%) As of February 14 at 8:10 AM GMT+1. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations National Geographic Magazine Showcases NanoString’s Spatial Biology Technology to Examine Cell Death in Alzheimer’s Disease SEATTLE, March 27, 2024--NanoString Technologies, Inc. (OTC: NSTGQ), a leading provider of life science tools for discovery and translational research, today announced that research using the company’s CosMx™ Spatial Molecular Imager (SMI) has been featured for a third time in National Geographic Magazine. Patient Square Capital, a Leading Health Care-Focused Investment Firm, Agrees to Acquire NanoString Technologies SEATTLE, March 11, 2024--NanoString Technologies, Inc. (OTC: NSTGQ) ("NanoString" or the "Company"), a leading provider of life science tools for discovery and translational research, today announced that it has reached an agreement with Patient Square Capital ("Patient Square"), a prominent health care investment firm, pursuant to which Patient Square will serve as the "stalking horse" bidder in conjunction with a court-supervised sales process. NanoString Announces Completion of Financing to Support Restructuring Process SEATTLE, February 09, 2024--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the Company has entered into a credit agreement with its existing lenders comprised of (a) $12,500,000 in new money term loans which have already been approved for funding pursuant to the February 5 interim order of the U.S. Bankruptcy court approving the credit facility, and (b) an additional $35,000,000 in new money term lo NanoString Takes Steps to Restructure Its Business and Protect Its Mission to Map the Universe of Biology SEATTLE, February 05, 2024--NanoString Technologies, Inc. (NASDAQ: NSTG) ("NanoString" or "the Company"), a leading provider of life science tools for discovery and translational research, today announced that steps are being taken to protect its business, customers, employees and its mission to "Map the Universe of Biology." With support from key creditors, NanoString and certain of its subsidiaries have voluntarily initiated a chapter 11 restructuring proceeding in the United States Bankruptcy NanoString Launches the CosMx 6,000 plex RNA Assay and Showcases Whole Transcriptome Imaging Capability SEATTLE, February 01, 2024--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial availability of the CosMx™ Human 6K Discovery Panel, the industry’s first single-cell spatial panel enabling research scientists to measure over 6,000 RNA targets, representing nearly every human biological pathway. Building on this breakthrough product developed for the CosMx Spatial Molecular Imager (SMI), Na NanoString’s CosMx SMI Achieves Whole Transcriptome Imaging at Single-Cell Resolution SEATTLE, January 07, 2024--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the release of the first public dataset of the whole transcriptome obtained at true single-cell resolution on the CosMx™ Spatial Molecular Imager (SMI). The data will be highlighted at the 42nd annual J.P. Morgan Healthcare Conference 2024 in San Francisco during NanoString’s corporate presentation on Wednesday, January 10, 20 NanoString Reports Inducement Grants Under Nasdaq Listing Rules SEATTLE, January 05, 2024--NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity inducement awards to 10 new employees. NanoString to Webcast Presentation from 42nd Annual J.P. Morgan Healthcare Conference SEATTLE, January 04, 2024--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a presentation from the 42nd annual J.P. Morgan healthcare conference, being held January 8-11, 2024. NanoString Comments on Delaware District Court Verdict SEATTLE, November 19, 2023--NanoString Comments on Delaware District Court Verdict NanoString Technologies to Present Portfolio of Cutting-edge Brain Research and Novel Spatial Biology Applications for Neuroscience SEATTLE, November 09, 2023--NanoString will present at the Society for Neuroscience meeting new brain research powered by its spatial profiling and spatial imaging platforms NanoString to Webcast Presentations from Upcoming Healthcare Conferences SEATTLE, November 09, 2023--NanoString to present at November conferences. NanoString Technologies Releases Operating Results for Third Quarter of 2023 SEATTLE, November 06, 2023--NanoString reports Q3 2023 Operating Results NanoString Customers Present First Data Using the Most Comprehensive Spatial Proteomics Panel Available SEATTLE, November 01, 2023--NanoString Technologies, a leading provider of life sciences tools for discovery and translational research, announced today the line-up of researchers joining NanoString at the 38th annual meeting of the Society for Immunotherapy of Cancer (SITC) to be held in San Diego, CA. 10x Genomics Comments on Second UPC Preliminary Injunction Decision 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the European Unified Patent Court ("UPC") has declined to issue a second preliminary injunction against NanoString Technologies, Inc. (Nasdaq: NSTG) based on European Patent 2 794 928 B1 ("the EP 928 patent," docket No 459996/2023). However, the injunctions granted by the Regional Court Munich I in May and by the UPC in September both remain in full force and effect and are not affected by today's NanoString Provides Preliminary Financial and Operational Highlights for Third Quarter of 2023 SEATTLE, October 10, 2023--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for the third quarter ended September 30, 2023, as well as a reorganization designed to accelerate the Company’s path to profitability. A*STAR’s Genome Institute of Singapore, NanoString and Next Level Genomics Establish Joint Lab to Advance Studies of Complex Diseases with Spatial Genomics SINGAPORE, October 03, 2023--A*STAR’s Genome Institute of Singapore (GIS), NanoString® Technologies, Inc. (NASDAQ: NSTG), and Next Level Genomics (NLG), today announced the establishment of a joint laboratory in Singapore focusing on the application of spatial biology to identify biomarkers that can predict disease progression and treatment response. The new lab, called the SpACE-Dx lab (Spatial Atlas of Clinical Evolution of Disease), will harness spatial multiomic (gene and protein expression) 10x Wins Injunction From Unified Patent Court Banning Sales of NanoString's CosMx Products in Europe 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the European Unified Patent Court ("UPC") issued a preliminary injunction against NanoString Technologies, Inc. (Nasdaq: NSTG) for infringing European Patent 4 108 782 B1 ("the EP 782 patent," docket No 459746/2023). The preliminary injunction, issued by a panel of four judges with both legal and technical expertise, prevents NanoString from selling or providing services using its CosMx Spatial Mo NanoString Comments on Unified Patent Court Order SEATTLE, September 19, 2023--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, commented on today’s order from the European Unified Patent Court (UPC) granting a preliminary injunction effective immediately in 17 Member States of the European Union against NanoString’s CosMx™ Spatial Molecular Imager (SMI) products for RNA detection in NanoString’s ongoing patent dispute with 10x Genomics and Harvard: NanoString to Host Virtual Spatial Genomics Summit September 19 SEATTLE, September 14, 2023--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, announced it will host its fifth annual Spatial Genomics Summit, September 19th. The two-hour virtual event will showcase advances in the rapidly expanding field of spatial biology with talks from scientific leaders harnessing the power and utility of our spatial platforms for discovery, drug development, the quest for biomarkers and compre NanoString Launches the Most Comprehensive Spatial Proteomics Panel Ever Offered SEATTLE, September 13, 2023--NanoString launches most comprehensive spatial proteomics panel to empower life sciences researchers to profile 500+ proteins simultaneously.
